Are you Dr. Javle?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 43 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Milind Javle, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 1995 - 1998- University at BuffaloResidency, Internal Medicine, 1993 - 1994
Grant Medical CollegeClass of 1991
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2007 - 2024
OK State Medical License 2020 - 2021
NY State Medical License 1998 - 2007- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer Start of enrollment: 2002 Jan 01
- Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Start of enrollment: 2002 Oct 01
- Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer Start of enrollment: 2003 May 01
- Join now to see all
Publications & Presentations
PubMed
- Utilizing Patient-derived Xenografts to Model Precision Oncology for Biliary Tract Cancer.Timothy P DiPeri, Kurt W Evans, Stephen Scott, Xiaofeng Zheng, Kaushik Varadarajan
Clinical Cancer Research. 2024-11-08 - Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response.Brian De, Prashant Dogra, Mohamed Zaid, Dalia Elganainy, Kevin Sun
Medrxiv. 2024-09-12 - 1 citationsPhase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations.Sarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, Ying Yuan, Daniel D Karp
NPJ Precision Oncology. 2024-07-31
Authored Content
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
Press Mentions
Gallbladder Cancer: 9 Facts About Symptoms, Diagnosis and TreatmentDecember 6th, 2023- MD Anderson Research Highlights for August 11, 2021August 11th, 2021
- The 4th OrigiMed International Summit Held in ShanghaiJune 8th, 2021
- Join now to see all
